{
    "pmcid": "8465657",
    "qa_pairs": {
        "How do AAV vectors contribute to the delivery of nanobodies for therapeutic applications?": [
            "AAV vectors provide long-term expression of therapeutic genes.",
            "AAV vectors are pathogenic, which limits their use in therapy.",
            "AAV vectors can only accommodate a single nanobody gene.",
            "AAV vectors are unstable and degrade quickly in vivo."
        ],
        "In the context of SARS-CoV-2, what makes nanobodies promising candidates for antiviral therapies?": [
            "Their ability to bind to conserved regions of viral proteins.",
            "Their inability to bind to the spike protein of SARS-CoV-2.",
            "Their high immunogenicity compared to conventional antibodies.",
            "Their short serum half-life without any modification."
        ],
        "What is a key advantage of using nanobodies derived from camelid heavy-chain antibodies compared to conventional antibodies?": [
            "Nanobodies have better tissue penetration due to their smaller size.",
            "Nanobodies have a higher molecular weight, making them more stable.",
            "Nanobodies can only bind to a limited range of epitopes.",
            "Nanobodies are less stable under extreme conditions."
        ],
        "What is a noted challenge in the use of nanobodies for therapeutic applications?": [
            "Nanobodies are rapidly cleared from the bloodstream due to their small size.",
            "Nanobodies have a high immunogenicity compared to human VH domains.",
            "Nanobodies are too large to penetrate tissues effectively.",
            "Nanobodies cannot be genetically manipulated easily."
        ],
        "What is a potential strategy mentioned to extend the serum half-life of nanobodies?": [
            "Fusion with albumin-binding domains or Fc regions.",
            "Increasing the molecular weight of nanobodies.",
            "Reducing the size of the nanobody to enhance circulation time.",
            "Using nanobodies without any modifications to extend half-life."
        ]
    }
}